|PART 1||PART 2 ..>|
Current and Future Treatment
Emmet B. Keeffe, MD, Stanford University Medical Center, Stanford, Calif. [Infect Med 17(9):603-613, 2000. © 2000 Cliggott Publishing Co., Division of SCP/Cliggott Communications, Inc.]
(Editorial note from Jules Levin: It's important to bear in mind that there are some difference between when a person has HCV alone compared to having coinfection with HIV and HCV. Slightly more coinfected patients have genotype 1 than genotype 2 (70 vs 80%). Response to HCV therapy is less foe genotype 1 than 2. A number of studies show HCV progresses more quickly for coinfected persons than for those infected with HCV alone. Thus, coinfected patients may be more likely to progress to advanced liver disease more quickly.
This may not be true for all coinfected patients. Some may not progress more quickly. One French study suggests that HAART improved cd4s and HIV viral load could slow HCV progression in coinfected patients to a rate equal to that in HCV alone. But this appears complicated as some patients with reasonably healthy cd4 and low or undetectable viral load have end stage liver disease or cirrhosis. Preliminary studies suggest coinfected pesons respond better to HCV therapy when CD4s are higher and HIV viral burden is under control. It appears accepted that cd4s over 200 are important to see a better response to HCV therapy. Perhaps, the higher the cd4s the better the response to HCV therapy may be. It's speculative but possible that starting HCV therapy in early HIV disease when cd4s are high and HIV viral load is low and before HIV therapy has started, may be a preferable time to start HCV therapy. The response to therapy may be better and the liver condition may be improved and better able to handle HIV medications).
Interferon alfa-2b, 3 million units tiw, plus ribavirin, 1000 to 1200 mg daily for 6 to 12 months, has shown an improvement of 2-fold or more for all measures of efficacy when compared with interferon monotherapy. In the next year, treatment of chronic hepatitis C will involve pegylated interferons, either alone or in combination with ribavirin. Therapy in 3 to 5 years will likely be multidrug combinations, including inhibitors of the hepatitis C virus (HCV) protease, helicase, or polymerase, with the aim of reducing serum levels or eradicating HCV RNA.
Hepatitis C virus (HCV) infection is the most common type of chronic viral hepatitis in the developed world.[1-3] The prevalence of antibody to HCV (anti-HCV) is 1.8% among the US population, with 74% of antibody-positive individuals demonstrating chronic infection with viremia. These prevalence rates suggest that approximately 3.9 million Americans have been infected with HCV, and 2.7 million are chronically infected.
Chronic hepatitis C impairs health- related quality of life, with natural history studies indicating that progression to cirrhosis occurs in at least 25% of patients, generally over a 10- to 30-year period.[1-3] After the development of cirrhosis, hepatocellular carcinoma occurs in 2% to 5% of these patients each year. However, it is important to keep in mind that most patients with chronic hepatitis C have a relatively benign natural history without development of progressive disease.[7,8]
Chronic hepatitis C is responsible for 8,000 to 10,000 deaths per year in the United States, and it is estimated that this death rate could increase to 38,000 per year by the year 2010. It is now the single most common indication for liver transplantation in the United States and Europe.
The high prevalence and potential morbidity of HCV infection makes treatment of chronic hepatitis C one of the more urgent priorities in infectious disease control.
Interferon-a monotherapy and, more recently, combination interferon-a and ribavirin therapy are the only treatments for chronic hepatitis C shown to be effective, although sustained response rates (normal serum aminotransferase levels and/or undetectable HCV RNA 6 months after completion of therapy) still occur in fewer than half of treated patients. Interferon-a at the standard dosages of 3 million units, or 9 mg, tiw for 6 months achieves a sustained biochemical and virologic response with histologic improvement in 7% to 20% of treated patients.[9-11]
Continuing interferon-a monotherapy for 12 to 18 months improves the sustained response rate to 15% to 30%. Results of the US and European trials with combination interferon alfa-2b plus ribavirin therapy in previously untreated patients show a doubling of these biochemical and virologic sustained response rates to approximately 40%, making combination interferon/ribavirin the current treatment of choice for chronic hepatitis C.[12,13]
Candidates for Therapy and Pretreatment Considerations
The primary goal of antiviral therapy for chronic hepatitis C is durable viral clearance as evidenced by the absence of HCV RNA in serum. A secondary goal is reduction of damage to the liver as determined by either persistently normal alanine aminotransferase (ALT) levels or improved liver biopsy results, with the expectation that this will delay or prevent cirrhosis, hepatocellular carcinoma, the need for liver transplantation, and death. Interferon therapy is indicated in patients with chronic hepatitis C who are at the greatest risk for progression to cirrhosis.[2,3] These patients are characterized by the following:
While pretreatment liver biopsy has been widely recommended and is standard in clinical trials evaluating new antiviral agents,[2,3] a recent cost-effectiveness analysis showed that routine liver biopsy increased the cost of managing patients without improving outcomes. A potentially acceptable alternative is to offer antiviral therapy to all patients who have chronic hepatitis C without contraindications or decompensated cirrhosis. Liver biopsy would be reserved for the exclusion of concomitant, alternative liver diseases and for management decisions -- for example, in patients not wanting therapy if fibrosis is mild or absent, or in patients who do not respond to standard therapy and are considering future, experimental therapies.
Pretreatment measurement of quantitative HCV RNA levels and HCV genotype are useful in forecasting the success rate of therapy and determining the length of combination interferon/ ribavirin treatment -- 6 months for patients with genotypes 2 or 3, 12 months for patients with genotype 1.[12,13]
Patients with histologically mild disease (grade 0 or 1 fibrosis) have a relatively benign natural history and may not require treatment.[2,3] Nevertheless, since nonfibrotic liver disease is associated with a higher likelihood of response to interferon, with treatment resulting in improved survival and cost savings, it may be judicious to offer such patients a trial of antiviral therapy.[12-14]
Several studies have evaluated the clinical status and response to treatment of patients with chronic viremia but persistently normal ALT levels on repeated determinations. Although advanced histologic changes are seen infrequently and cirrhosis is rare, abnormal liver histology is found in the majority of such patients. The results of several treatment trials indicate that a sustained virologic response is uncommon, with elevated ALT levels developing in some patients during treatment and persisting thereafter. The current recommendation is not to perform biopsy or administer treatment in patients with persistently normal ALT levels.[2,3] Further studies are necessary to determine whether combination interferon/ribavirin treatment will result in better outcomes in this subset of HCV-infected patients.
Patients with compensated cirrhosis have a 29% risk of decompensation and a 21% risk of death over 10 years; once decompensation occurs, the 5-year survival is only 50%. Since the efficacy of interferon in patients with decompensated cirrhosis has not been documented, these patients should be considered for liver transplantation. Patients with compensated cirrhosis secondary to chronic hepatitis C have reduced sustained response rates to interferon therapy.[2,3] However, data from more recent studies suggest that interferon therapy improves liver function and may prevent or delay the onset of decompensation or the development of hepatocellular carcinoma in patients with cirrhosis, particularly those who show a complete response to interferon. Thus, cautious use of interferon with close monitoring for cytopenias may be warranted in patients with chronic hepatitis C who have compensated cirrhosis.
Heavy drinkers with chronic hepatitis C are at risk for more advanced histologic disease secondary to HCV infection and should be encouraged to abstain from alcohol.[2,3] Recently published retrospective and prospective studies have demonstrated that the occurrence of acute hepatitis A in patients with chronic hepatitis C and other chronic liver diseases is associated with increased morbidity and mortality.[19,20]
Although not directly studied, there is also probably a worse outcome of acute hepatitis B in patients with preexisting chronic liver diseases, including chronic hepatitis C. The safety and efficacy of hepatitis A vaccine in patients with chronic liver disease was recently demonstrated; hepatitis B vaccine also has effectiveness in chronic liver disease, although higher doses of the vaccine may be required.
These observations led to the recommendation by the CDC that all patients with chronic liver disease receive hepatitis A vaccine. The NIH Consensus Development Conference recommended that all patients with hepatitis C be screened for prior immunity and undergo vaccination for both hepatitis A and B if susceptible.
Three types of interferon-a have been studied and are approved for the treatment of chronic hepatitis C (Table 2):
Although these interferons have demonstrated some differences in efficacy in subgroup analyses, the NIH Consensus Development Conference panel concluded that all 3 interferons have generally comparable safety and efficacy in the treatment of chronic hepatitis C when given at the standard dosages of 3 million units, or 9 µg, tiw for 12 months or longer.
Response rates to interferon therapy vary according to dosage and duration of therapy and baseline characteristics of treated patients. Duration of treatment appears to be more important than the dosage of interferon in achieving a sustained response. (editorial note: I think this is disproven by pegylated inteferon which delivers higher levels of interferon which are sustained for a longer period of time and show superior response rates). Only 7% to 20% of patients have a long-term sustained response after 6 months of therapy; treatment for 12 to 24 months is associated with a sustained virologic response of 15% to 30% and a significantly greater decrease in hepatic inflammation.[2,3,11] The efficacy of higher interferon doses and daily induction therapy is currently under evaluation.
Pretreatment factors associated with a greater likelihood of response to interferon include:
(Editorial note: it appears women under 40 respond better than men or women over 40 so age and gender may be factors. A recent preliminary study suggests that pre-menopausal women respond better to therapy than post-menopausal and so estrogen replacement therapy appeared to improve response rates for post-menopausal women. In HIV there may be unidentified drug-drug interactions between HIV medications and estrogen replacement therapy. As well, there may be additional health considerations in taking estrogen replacement therapy. This may have to be studied further. Persons of lighter weight and with less fatty liver, which may be related to diet, may respond better to therapy).
A remarkable and unexplained poor response to interferon has been shown in African Americans when compared with white patients, with end-of-treatment and sustained virologic responses of only 5% and 2% versus 33% and 12%, respectively. (editorial note: response to pegylated interferon appears improved for caucasians and African Americans, yet the response rate is less for African Americans. It is uncertain why African Americans respond less well, but seceral studies show over 90% of African Americans are genotype 1. Studies suggest that African Americans may progress less quickly and a recent study suggested that genotype 1 may progress less quickly).
Responses to antiviral therapy for chronic hepatitis C are defined by convention on the basis of various outcomes. A biochemical response is defined on the basis of a normal ALT level and a virologic response by an undetectable level of serum HCV RNA. The time of these findings is expressed either as an end-of-treatment response or as a long-term post-treatment sustained response. Persistence of a biochemical and/or virologic response for 6 months or more after cessation of therapy is the operational definition of a sustained response.
Evidence is now accumulating that a sustained virologic response 6 months after completion of interferon therapy predicts a long-term clinical response over 4 to 10 years.[27,28] In studies by Marcellin and coauthors and Lau and associates, there was permanent loss of serum HCV RNA in more than 95% of patients and improvement of liver histology, including evidence of regression of hepatic fibrosis, in noncirrhotic patients. These studies suggest that some patients may indeed be cleared of chronic HCV infection and that a reduction in mortality should be expected if cirrhosis, with its risk of progression to hepatocellular carcinoma, can be prevented.
Nonresponse is defined as persistently elevated ALT levels and/or detectable serum HCV RNA. A variant of nonresponse called "breakthrough" is defined as an initial decrease of ALT levels into the normal range or the disappearance of detectable HCV RNA with subsequent elevation of ALT levels or presence of detectable HCV RNA while the patient is still receiving treatment. Failure to clear HCV RNA after 12 weeks of interferon monotherapy or 24 weeks of combination therapy predicts the lack of a sustained virologic response and has been considered reason to stop therapy.[2,3,12,13] However, histologic improvement may still occur in nonresponders at the end of a complete course of therapy, and thus continuation of therapy may be beneficial. A large NIH 5-year study of the potential benefit of long-term interferon therapy in nonresponders with advanced fibrosis is currently under way.
Re-treatment With Interferon Monotherapy
Re-treatment studies have been performed on patients with chronic hepatitis C who were nonresponders or relapsers after a course of interferon monotherapy. Re-treatment response rates have been highly variable and depend on the response to the initial course of treatment. The only treatment strategies that have shown some favorable results with interferon monotherapy are using a higher dose for a longer period or using a different interferon. In general, response rates are much higher in patients who previously responded and relapsed than in patients who did not respond to an initial course of therapy.
Re-treatment of relapsers with interferon alfacon-1 at a higher dosage of 15 mg tiw for 12 months achieved a 58% sustained virologic response, similar to the re-treatment response rate of combination interferon alfa-2b and ribavirin. The substantially higher tolerability of interferon monotherapy compared with combination therapy -- rates of discontinuation of approximately 5% to 10% versus 15% to 20%, respectively -- makes monotherapy an excellent re-treatment option for those who relapsed following prior therapy.
In contrast to the reasonably good results with re-treatment of relapsers, the cumulative data indicate that nonresponders to interferon therapy achieve only modest responses with re-treatment, as shown by a 13% sustained virologic response to interferon alfacon-1 at a dosage of 15 mg tiw for 12 months. However, approximately 30% of nonresponders have the breakthrough subtype of nonresponse. With re-treatment with interferon alfacon-1 at 15 mg tiw for 12 months, 27% of those with a viral breakthrough had a virologic sustained response, compared with 8% of nonresponders without breakthrough. Therefore, prior nonresponders with breakthroughs have a better chance of responding to re-treatment.
Combination Interferon With Ribavirin
Since therapy for chronic hepatitis C with interferon-a is less than ideal, numerous other approaches have been studied. Results of recently concluded trials comparing standard interferon-a monotherapy with interferon alfa-2b/ribavirin combination therapy have shown an approximate doubling in response rate for all measures of efficacy.[12,13] Although the rate of drug-induced adverse effects is higher, the overall safety profile of combination therapy is acceptable.[12,13]
Ribavirin is a nucleoside analogue typically given orally, 1000 to 1200 mg/d. Combination therapy with ribavirin and interferon-a initially showed promise in uncontrolled pilot studies, with later confirmation in randomized trials. Results of the recently concluded US and European trials comparing standard interferon-a monotherapy with interferon alfa-2b plus ribavirin have shown significant improvement in response rates for all measures of efficacy in treatment-naive patients with chronic HCV infection,[12,13] including:
These studies have also shown important differences in outcome based on genotype. Patients with genotype 1 had increased rates of sustained virologic response with 48 weeks versus 24 weeks of combination therapy, while patients with other genotypes derived no added benefit after the additional 24 weeks of combination therapy.
In patients who relapse after an end-of-treatment response with interferon-a alone, combination treatment with interferon/ribavirin for 24 weeks has achieved a 49% response rate compared with 4% with interferon alone at standard dosage. However, nonresponders to interferon-a alone rarely achieve a sustained response with combination treatment.
The chief side effect of ribavirin therapy is a dose-dependent hemolytic anemia, which is reversible and usually stabilizes after 4 to 8 weeks of treatment. Most patients experience a drop in hemoglobin level of 2 g/dL, and some patients may become severely anemic, necessitating discontinuation of therapy. Other common side effects associated with ribavirin treatment are respiratory symptoms (cough, dyspnea); skin disorders (pruritus, rash, dry skin); neuropsychiatric symptoms (insomnia, depression, anxiety); and GI disorders (anorexia, dyspepsia). Ribavirin is potentially teratogenic, and contraception is mandatory during treatment and for 6 months after therapy.
In the US multicenter study of combination therapy, discontinuation of therapy was necessary in 8% to 21% of patients in the 4 treatment groups and more common in the combination groups. In the 2 combination-treatment groups, dose reduction was required in 7% to 9% of patients because of anemia and 13% to 17% for other reasons. The most frequent reason for discontinuation of therapy in all groups in the US trial was the development of psychiatric symptoms, primarily depression.
Contraindications to combination therapy with interferon and ribavirin are listed in Table 4. Some of these contraindications relate primarily to ribavirin therapy. For example, patients with preexisting anemia usually cannot tolerate the degree of hemolysis that occurs with ribavirin. Patients with significant cardiovascular disease are also at risk if severe anemia develops during therapy. Patients with chronic hepatitis C and the above baseline conditions should be treated with interferon monotherapy rather than combination therapy.
Induction Interferon Therapy
The failure of interferon-a monotherapy may be associated with increased quasispecies diversity and high viral load. (Quasispecies are closely related but distinct genomes within the same HCV genotype that occur over time from viral mutations.) Therefore, as in HIV infection, aggressive initial therapy for chronic hepatitis C with interferon may be appropriate.
Interferon-a, 10 to 15 million units daily, has shown significantly better early antiviral efficacy than a dosage of 5 million units daily or the standard dosage of 3 million units tiw.[33,34] Initial intervention with a high-dose induction interferon regimen, resulting in a rapid exponential decline in the HCV RNA level, is likely to show enhanced effectiveness in determining the initial response and may prove to be the most effective way to achieve sustained HCV clearance. However, current studies are too limited to determine whether early viral clearance will increase the ultimate sustained virologic response rate.
Based on the similar hypothesis of induction therapy, a long-acting pegylated formulation of interferon (PEG-IFN) (formed by the attachment of the inert polymer polyethylene glycol to interferon) may help reduce the fluctuating effects seen with the 3-times-per-week dosing regimen with standard interferon, which has a serum half-life of 4 to 6 hours. PEG-IFN has a decreased renal clearance with a half-life of more than 90 hours and is administered once a week subcutaneously.
A major research program is being conducted to assess the safety and efficacy of PEG-IFN alfa-2a or alfa-2b in the treatment of chronic HCV infection. Data from ongoing studies indicate that the safety profile of PEG-IFN alfa-2a (180 mg once a week) is comparable to that of standard regimens using interferon alfa-2a (3 million units tiw), but the sustained virologic response rate of 36% is equivalent to that with treatment with combination interferon and ribavirin.[12,13] Studies are also under way to assess the safety and efficacy of PEG-IFN combined with ribavirin.
(Editorial note: since this publication, several Pegasys monotherapy studies have shown sustained virologic response rates of 28-38%, and a Pegasys+RBV combination study showed a SVR of 56%. A PegIntron monotherapy study showed a response rate of 25% and combination response rate of 56%. When Schering conducted a retrospective sanalysis at weight and RBV concentrstion based on weight, they found that 61% who had a certain higher weight based concentration of RBV had a SVR. These results are controversial because these were patients of lighter weight (lighter weight patients tend to respond better). The study was not prospective-in other words, patients did not actually receive a higher RBV dose from the start of the study, all patients received the same RBV dose. IN HCV/HIV coinfection there is some concern that higher RBV dosing may lead to more side effects. A prospective study by Schering supposedly being planned).
Future Antiviral, Immunomodulatory, and Combination Treatments
Although current interferon-based combination therapy can achieve sustained virologic response rates of up to 40%, the remaining 60% of treated patients do not experience significant long-term benefits. Clearly, better therapies are needed, especially for the interferon nonresponders. A number of newer approaches to the eradication or control of HCV infection are undergoing laboratory testing or have shown some efficacy in the control of other viral infections but have not reached the stage of clinical trials in patients with chronic hepatitis C.
One promising approach, which has demonstrated success in the control of HIV infection, is the inhibition of viral replication by the use of enzyme inhibitors to HCV protease, helicase, or replicase. While this approach appears to effectively suppress viremia, a potential limitation is the emergence of drug-resistant mutations. Inhibition of viral replication might also be achieved by:
Other potential future approaches to the treatment of chronic HCV infection involve modulation of the host immune response. There is speculation that patients who develop chronic HCV infection have a weak TH1 cytokine response and strong TH2 response, and are thus unable to clear the virus. Therefore, treatments that might alter this balance to create a stronger TH1 response are under exploration.
Most probably, future treatment with the goal of controlling or eradicating chronic HCV infection will include several of the above approaches -- multidrug regimens to inhibit viral entry into the hepatocyte, suppress viral replication, and alter immune response to the virus.
Grading of degree of fibrosis on liver biopsies from patients with hepatitis C
|Grade Degree of fibrosis|
FDA-approved interferon (IFN) therapy for chronic hepatitis C virus infection
|Name||Company||Approved US dosage|
| IFN alfa-2b
|Schering-Plough||3 million units tiw for 18 - 24 mo|
| IFN alfa-2a
|Roche||3 million units tiw for 12 mo|
| IFN alfacon-1
|Amgen||9 mg or 15 mg* tiw for 6 mo|
|Schering-Plough|| IFN 3
million units tiw plus ribavirin plus ribavirin
1000 - 1200 (Rebetron) mg/d for 6 - 12 mo
*15-mg alfacon-1 licensed for re-treatment only.
PegIntron+RBV study results reported at EASL 2001: http://www.natap.org/2001/36theasl/part4easl050101.htm
Pegasys+RBV study results reported at DDW 2001: http://www.natap.org/2001/ddw/pegylated052301.htm
Sustained virologic response rates after treatment of chronic hepatitis C with IFN alfa-2b plus RBV versus IFN alone in US and European studies
IFN, interferon; RBV, ribavirin.
Contraindications to combination IFN and RBV therapy
IFN, interferon; RBV, ribavirin.
1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
2. National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(suppl 1):2S-10S.
3. Consensus Panel: EASL International Consensus Conference on Hepatitis C: Paris, 26-28 February 1999. Consensus statement. J Hepatol. 1999;30:956-961.
4. Alter MJ, Kruszon-Moran D, Nainon OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
5. Bonkovsky HL, Woolley JM, for the Consensus Interferon Study Group: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology. 1999;29:264-270.
6. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(suppl 1):34S-38S.
7. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-1233.
8. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000; 132:105-111.
9. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatology. 1996;24:778-789.
10. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(suppl 1):83S-88S.
11. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol. 1999; 14(suppl):S12-S18.
12. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
14. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits and costs. JAMA. 1998;280:2088-2093.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825-832.
16. Marcellin P, Martinot M, Boyer N, L*vy S. Treatment of hepatitis C patients with normal aminotranferase levels. Clin Liver Dis. 1999;3: 843-853.
17. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
18. Poynard T, Moussali J, Ratziu V, et al. Effect of interferon therapy on natural history of HCV-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 1999;3:869-881.
19. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201-205.
20. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-290.
21. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881-886.
22. Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hepatitis Rev. 1999;5:77-88.
23. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1996;45(RR-15):1-30.
24. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis. Hepatology. 1997;26(suppl 1):122S-127S.
25. Reddy KR, Hoofnagle JH, Tong MJ, et al: Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology. 1999;30: 787-793.
26. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26(suppl 1):71S-77S.
27. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med. 1997;127:875-881.
28. Lau DT, Kleiner DE, Ghany MG, et al. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
29. Camm C, Giunta M, Chemello L, et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology. 1999;30:801-807.
30. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998;27:1136-1143.
31. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1999; 339:1493-1499.
32. Heathcote EJ, James S, Mullen KD, et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. Hepatology. 1999;30:562-566.
33. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997;26:226-231.
34. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy in interferon-alpha therapy. Science. 1998; 232:103-107.
35. Shiffman M, Pockros PJ, Reddy RK, et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C [abstract]. Gastroenterology. 1999;116:A1275.
36. Davis GL, Nelson DR, Reyes GR. Future options for the management of hepatitis C. Semin Liver Dis. 1999;19(suppl 1):103-112.
|www.natap.org||to top||to PART 2 ..>|